Trial reportNature2026
Correlates of HIV-1 control after combination immunotherapy.
Abstract readClinical Trial
In one paragraph
Trial report in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- MVA.HIVconsvX vaccination-evoked T cell expansion inversely associates with age in people with HIV-1 on antiretroviral therapy.The Journal of clinical investigation · 2026Trial
- Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial.Nature medicine · 2026Article
- In vivo effect of anti-PD-1 on HIV-specific CD8+T-cells in men with HIV.Nature communications · 2026Article
- Persistent cytolytic CD8Cell reports. Medicine · 2026Article
- Unique CD8bioRxiv : the preprint server for biology · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Scientific synergy between prophylactic and therapeutic HIV vaccines-prevention and cure.NPJ vaccines · 2026Article
- HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV.Research square · 2026Article
- The HIV Reservoir and Immune Landscape Across the Life Course of Women: Implications for Cure Strategies.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control.Current opinion in HIV and AIDS · 2026Review
- Impact of sex differences in adult and paediatric HIV-1 cure.Current opinion in HIV and AIDS · 2026Review
- Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodies.bioRxiv : the preprint server for biology · 2026Article
- What's Hot in HIV in 2025-A Basic and Translational Science Review From IDWeek 2025.The Journal of infectious diseases · 2026Review
- 5' leader defects drive persistent HIV-1 viremia on long-term ART.Nature communications · 2026Article
- Immune activation during broadly neutralizing antibody-mediated HIV suppression prior to post-intervention control.bioRxiv : the preprint server for biology · 2026Article
- Review
- Charting the Path Forward for HIV Immune-Based Prevention: Contributions of the Division of AIDS at NIAID.Vaccines · 2026Article
- Antigen-boosted CD4CAR T cells fail to expand or control viremia in multiple nonhuman primate models of HIV.Blood · 2026Article
- Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies.Communications medicine · 2026Review
Corrections and comments
- Update of
Authors and funding
40 authors.
M J Peluso *Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0585-6230
D A Sandel *Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-4095-2036
A N Deitchman *Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-4722-463X
S J KimDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
T DalhuisenDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9132-0496
H P TummalaDepartment of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0005-9493-3497
R TibúrcioDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
L ZemelkoDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
G M BorgoDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
S S SinghDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
K SchwartzDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
M DeswalDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
M C WilliamsDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
R HohDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
M ShimodaDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-6627-4624
S NarpalaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
L SerebryannyyVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
M KhaliliDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9178-9139
E VendrameGilead Sciences, Foster City, CA, USA.ORCID 0000-0002-5595-1773
D SenGuptaGilead Sciences, Foster City, CA, USA.
L S WhitmoreDepartment of Immunology, Center for Innate Immunity and Immune Disease, School of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0002-8721-8701
J Tisoncik-GoDepartment of Immunology, Center for Innate Immunity and Immune Disease, School of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0003-1381-265X
M GaleDepartment of Immunology, Center for Innate Immunity and Immune Disease, School of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0002-6332-7436
R A KoupVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
J I MullinsDepartment of Microbiology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-4461-8158
B K FelberBasic Research Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.ORCID 0000-0001-8925-8128
G N PavlakisBasic Research Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
J D ReevesLabcorp-Monogram Biosciences, San Francisco, CA, USA.
C J PetropoulosLabcorp-Monogram Biosciences, San Francisco, CA, USA.ORCID 0000-0001-5496-8090
D V GliddenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
M H SpitzerDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5291-3819
L GamaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
M CaskeyDepartment of Clinical Investigation, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-1727-8693
M C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-0592-8564
K W ChewDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-4865-4348
T J HenrichDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-6684-0622
S A YuklDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
L B CohnFred Hutchinson Cancer Center, Seattle, WA, USA.
S G DeeksDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA. steven.deeks@ucsf.edu.ORCID 0000-0001-6371-747X
R L RutishauserDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA. rachel.rutishauser@ucsf.edu.
Funding
Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1MVirology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6MDelaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0MUCLA-CDU CFARP30AI152501 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SCOTT G KITCHEN · 2022 to 2026
$15.6MThe heterogeneous HIV expressing reservoir: dynamics, persistence mechanisms, tissue distribution, and contribution to reboundP01AI169606 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Steven A Yukl · 2022 to 2026
$9.3MSupplement to A Multi-omics Approach to Immune Responses in HIV Vaccination and InterventionP01AI178375 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DENNIS J. HARTIGAN-O'CONNOR, Rachel Lena Rutishauser · 2023 to 2026
$8.5MTraining in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4MRestorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5MTargeting HIV-specific T cell differentiation programs to enhance post-treatment control of HIVR01AI170239 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Rachel Lena Rutishauser · 2022 to 2026
$4.0MImmune determinants of progression from Oral Epithelial Dysplasia to Oral Squamous Cell Carcinoma by precision multiplexed imagingR01DE032033 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Matthew Spitzer · 2022 to 2026
$3.8MUnderstanding and targeting the HIV-expressing reservoir to reduce immune activationR01AI183666 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT, Steven A Yukl · 2024 to 2026
$2.4MMentoring Multidisciplinary Patient-Oriented Research in Viral HepatitisK24AA022523 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KHALILI, MANDANA · 2013 to 2023
$1.9MGates Foundation INV-002707NCATS NIH HHS UL1 TR001872NIAAA NIH HHS K24 AA022523NIAID NIH HHS K23 AI157875NIAID NIH HHS K23 AI162249NIAID NIH HHS K24 AI174971NIAID NIH HHS P01 AI169606NIAID NIH HHS P01 AI178375NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI152501NIAID NIH HHS R01 AI170239NIAID NIH HHS R01 AI183666NIAID NIH HHS T32 AI060530NIAID NIH HHS UM1 AI164560NIDCR NIH HHS R01 DE032033NIGMS NIH HHS T32 GM136547NIH HHS S10 OD018040
Abstract
The identification of therapeutic strategies to induce sustained antiretroviral therapy (ART)-free control of HIV infection is a major priority
Indexed as
AIDS VaccinesHIV-1HIV InfectionsImmunotherapyAdultAntibodies, NeutralizingBroadly Neutralizing AntibodiesCD8-Positive T-LymphocytesFemaleHIV AntibodiesHumansMaleMiddle AgedProof of Concept StudyViral LoadAIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV Antibodies
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.